Back to Schemes

Rare Neurological Disease (RND) Gene Panel

Product Code: 01-RND-27

From £467.00

Deadline to order: 30/11/2026

NGS gene panel testing for Rare Neurological Diseases (Germline DNA) (including targeted panel testing/ virtual panel /clinical exome / WES / WGS)

Target/Genes:

  
Panel testing of genes associated with rare neurological disease (RND). The scope of this EQA is broadly in line with the genes designated high evidence (green) on the Genomics England RND panel.
 
 

Technology:

CNV, MLPA, NGS, Panel testing, Whole exome sequencing, Whole genome sequencing

Language:

English, French, German, Italian, Spanish

Sample Type:

DNA (in TE Buffer)

Accredited:

Yes

Sample dispatch to your laboratory:

Jan-27

Test and Submit Results:

January - March 2027 (for exact dates, please see scheme instructions)

Final Results and Certificate:

 August 2027

You can complete purchase on our secure partner site.

How it works

Register

  • Enrol before the closing date (30/11/2026)
  • EMQN ships EQA samples or digital cases

Test & submit results

  • Analyse samples in your routine workflow
  • Upload results via your website account (January - March 2027 (for exact dates, please see scheme instructions))

Review & get certified

  • EMQN assesses your data
  • Receive your individual results, EQA summary report & certificate of participation ( August 2027)

EQA Assessment

The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.

Sample Details

Three mock clinical cases, two with matching samples and one virtual case will be provided.

Approximately 2µg DNA per sample is provided. Complete information will be available in scheme instructions.

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form. Testing can be performed using any appropriate panel for genes associated with rare neurological disease. To account for differing panel compositions, variants outside the stated scope of an individual laboratory’s panel will be excluded from their assessment. Only variants that have been validated in the test samples will be assessed. 

This EQA is provided in collaboration with the European Reference Network for Rare Neurological Diseases (ERN-RND) – see website for more information.

No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc). 

Enquire about this scheme

Contact Information

added wishlist!
View Wishlist

0

View Wishlist

Register Interest

Express your interest in ''.